longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Ocular Therap

OCUL

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -5.73, within the reasonable range, cheaper than 25.71% of the time in the past 5 years, and the industry ranks 168/256, the industry Median -1.41.

-5.73xP/E
$7.87Stock price
$-1.37Earnings per share
-5.73xP/E
Stock price$7.87Earnings per share$-1.37

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-7.45x
Typical range
-10.92x–-5.28x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0306090120

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-56.00x149.86%$58.48B
BAYZFUSBayer Aktiengesellschaft
-26.95x--$54.38B
BAYRYUSBayer
-27.05x--$54.58B
VTRSUSViatris
-50.68x107.75%$20.81B
ELANUSElanco Animal Health
-56.77x129.36%$11.30B
VREOFUSVIREO GROWTH INC
-149.60x--$10.04B
AXSMUSAxsome Therap
-50.88x26.69%$9.75B
CURLFUSCuraleaf Holdings, Inc.
-158.98x--$8.27B
BLTEUSBelite Bio
-65.57x29.87%$6.71B
DFTXUSDefinium Therapeutics
-14.51x53.61%$5.13B
MANEUSVeraDermics
-47.20x97.44%$4.92B
EWTXUSEdgewise Therapeutics
-21.58x137.29%$4.26B
AMLXUSAmylyx Pharmaceuticals
-24.16x1.76%$3.68B
ELVNUSEnliven Therapeutics
-32.17x1.17%$3.41B
TARSUSTarsus Pharmaceuticals
-72.41x205.82%$3.37B
RGCUSRegencell Bioscience
-435.82x--$3.07B
MBXUSMBX Biosciences
-26.67x30.54%$2.78B
SUPNUSSupernus Pharma
-23.26x70.59%$2.56B
TRLVUSTrulieve Cannabis
-5.05x198.82%$2.39B
GPCRUSStructure Therapeutics
-10.85x102.05%$2.33B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.